Consistent with the role of Sox2 as a transcription factor required for GSC tumorigenicity,47 we found that TAT-Cx43266–283 strongly decreased GSC tumorigenicity, as judged by the lower number of human glioma cells found 1 month post-implantation. The gene discussed is SOX2; the disease is central nervous system cancer.